GSK/Theravance secure CHMP nod for Anoro in COPD
This article was originally published in Scrip
Executive Summary
The EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of GlaxoSmithKline/Theravance's Anoro (umeclidinium/vilanterol; UMEC/VI) in the EU.